Tigatuzumab
| Tigatuzumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Tigatuzumab is a monoclonal antibody designed for the treatment of various types of cancer. It is specifically developed to target and bind to the death receptor 5 (DR5), a protein overexpressed in many types of cancer cells. By binding to DR5, tigatuzumab triggers a process known as apoptosis (programmed cell death) in the cancer cells, thereby inhibiting tumor growth.
Mechanism of Action
Tigatuzumab works by targeting the DR5 receptor on the surface of cancer cells. DR5 is a member of the tumor necrosis factor (TNF) receptor superfamily, which plays a crucial role in triggering apoptosis. The binding of tigatuzumab to DR5 activates the receptor's apoptotic signaling pathways, leading to the death of the cancer cell.
Clinical Trials
Tigatuzumab has been evaluated in various clinical trials for its effectiveness and safety in treating different types of cancers, including colorectal cancer, non-small cell lung cancer, and breast cancer. These studies assess the antibody's ability to improve survival rates and reduce tumor size as part of combination therapies or as a monotherapy.
Development and Approval
The development of tigatuzumab is part of a broader effort to harness the power of the immune system in fighting cancer. As of the last update, tigatuzumab is still undergoing clinical trials and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use.
Potential and Challenges
While tigatuzumab shows promise in targeting and killing cancer cells, its development faces challenges typical of monoclonal antibody therapies, such as immune system reactions, high production costs, and the need for precise targeting to avoid affecting normal cells.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD